BeiGene, Ltd. (NASDAQ:BGNE) Shares Purchased by Fmr LLC

FMR LLC increased its stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 0.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,660,011 shares of the company's stock after buying an additional 12,855 shares during the period. FMR LLC owned 1.70% of BeiGene worth $372,689,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Blue Trust Inc. lifted its holdings in shares of BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company's stock valued at $28,000 after purchasing an additional 75 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in BeiGene in the third quarter valued at about $36,000. SG Americas Securities LLC acquired a new stake in BeiGene in the third quarter worth about $105,000. PFG Investments LLC acquired a new stake in BeiGene in the third quarter worth about $210,000. Finally, Truist Financial Corp grew its stake in shares of BeiGene by 10.1% during the second quarter. Truist Financial Corp now owns 1,521 shares of the company's stock worth $217,000 after acquiring an additional 140 shares during the last quarter. Institutional investors own 48.55% of the company's stock.

BeiGene Price Performance

Shares of NASDAQ:BGNE traded up $8.84 during trading on Friday, reaching $215.00. 258,633 shares of the company's stock traded hands, compared to its average volume of 285,123. The firm has a market cap of $20.94 billion, a PE ratio of -26.09 and a beta of 0.63. BeiGene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $248.16. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The company has a 50-day simple moving average of $212.42 and a 200-day simple moving average of $184.77.

BeiGene (NASDAQ:BGNE - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.26 million. During the same period in the prior year, the business posted $2.01 EPS. BeiGene's revenue was up 28.2% compared to the same quarter last year. As a group, analysts predict that BeiGene, Ltd. will post -5.38 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Titus B. Ball sold 137 shares of the business's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.94, for a total transaction of $26,021.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Xiaodong Wang sold 40,468 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $190.10, for a total value of $7,692,966.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 63,538 shares of company stock worth $12,594,017. Insiders own 7.43% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on BGNE. TD Cowen lifted their target price on shares of BeiGene from $254.00 to $260.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. boosted their price objective on shares of BeiGene from $200.00 to $235.00 and gave the company an "overweight" rating in a report on Tuesday, October 22nd. Citigroup raised their target price on BeiGene from $269.00 to $288.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. StockNews.com lowered BeiGene from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Finally, JMP Securities initiated coverage on BeiGene in a research report on Wednesday, September 18th. They issued a "market outperform" rating and a $288.00 target price on the stock. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $247.07.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.